nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

24.01.2020 | special report

The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers

verfasst von: Prof. Helmut H. Popper, M.D., Ulrike Gruber-Mösenbacher, Georg Pall, Leonhard Müllauer, Maximilian Hochmair, Dagmar Krenbek, Luka Brcic, Katja Schmitz, Bernd Lamprecht, Josef Eckmayr, Wolfgang Hilbe, Georg Hutarew, Peter Errhalt, Rainer Kolb, Robert Pirker, Ulrike Setinek, Gerald Webersinke, Gudrun Absenger, Tamara Hernler, Markus Rauter, Richard Wasicky

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Summary

The knowledge on molecular alterations in lung cancer have increased during the last decade considerably. Almost every year new genes were detected being targetable, and drugs have been developed and provided for those patients being diagnosed with such a lung cancer. Therefore, it was necessary to update previous recommendations to facilitate a uniform handling for the diagnosis and molecular tests of lung cancer specimen all over Austria. Originally mutation of the epidermal growth factor receptor (EGFR) was the only actionable molecular alteration, now there are more than 10 driver mutations known, and more are detected, and clinical studies are performed. In addition, the technique to test for these mutations have improved, next generation sequencing has opened the option to test several genes in one test. Immuno-oncology has entered the field, and besides the checkpoint death receptor and ligand molecules PD-1/PD-L1 more molecules have been detected and are also tested in clinical studies.

To provide equal opportunities to our patients the tests have to be implemented in all pathological institutes involved in lung cancer management. Because pathologists as part of the tumor board have to explain the diagnosis and the molecular alterations and suggest possible treatment options, the tests should be performed in-house, which will provide the optimal quality control.

Vorheriger Artikel Young hematologists and medical oncologists in focus

Nächster Artikel Ensuring center quality, proper patient selection and fair access to chimeric antigen receptor T-cell therapy: position statement of the Austrian CAR-T Cell Network

MIC = mononuclear immune cells: macrophages, lymphocytes, dendritic cells

Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, et al. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the association for molecular pathology and college of American pathologists. J Mol Diagn. 2017;19(3):341–65. https://doi.org/10.1016/j.jmoldx.2017.01.011.CrossRefPubMed

Yatabe Y. RT_PCR and nonmultiplex platforms. In: Hirsch FR, Tsoa MH, Yatabe Y, editors. IASLC Atlas of ALK and ROS1 testing in lung cancer. 2nd ed. North Fort Myers: Editorial Rx PRess; 2016. pp. 63–7.

Sholl L. Molecular diagnostics of lung cancer in the clinic. Transl Lung Cancer Res. 2017;6(5):560–9. https://doi.org/10.21037/tlcr.2017.08.03.CrossRefPubMedPubMedCentral

Sequist LV, Neal JW. Personalized, genotype-directed therapy for advanced non-small cell lung cancer. Edited by UpToDate. Waltham, MA: UpToDate, Inc.; 2019.

Kashofer K, editor. Tumor mutational burden (TMB) and neoantigens as immunological therapy predictors? 43rd Annual Meeting of the AustrianSociety of Pneumology an of the Austria Thoracic Society; Vienna. 2019.

Roy-Chowdhuri S, Goswami RS, Chen H, Patel KP, Routbort MJ, Singh RR, et al. Factors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol. 2015;123(11):659–68. https://doi.org/10.1002/cncy.21597.CrossRefPubMed

Wistuba I. ALK and ROS1 testing with NGS. In: Tsao MH, Hirsch FR, Yatabe Y, editors. IASLC Atlas of ALK and ROS1 testing in lung cancer. North Fort Myers: Editorial Rx Press; 2016. pp. 69–72.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol. 2018;13(9):1248–68. https://doi.org/10.1016/j.jtho.2018.05.030.CrossRefPubMed

Böcking AS, Juncker K. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. In: Deutsche Krebsgesellschaft, AWMF, editors. Leitlinienprogramm Onokologie. Langversion 1.0. 2018. pp. 113–26.

10.

Thunissen E. ALK testing with IHC. In: Tsao MH, Hirsch FR, Yatabe Y, editors. IASLC atlas of ALK and ROS1 testing in lung cancer. North Fort Myers: Editorial Rx PRess; 2016. pp. 25–33.

11.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline focused update. Arch Pathol Lab Med. 2018;142(11):1364–82. https://doi.org/10.5858/arpa.2018-0902-SA.CrossRefPubMed

12.

Krenbek D, editor. Which biomarkers do we need and what can they do? 43rd Annual Meeting of the Austrian Society of Pneumology and of th Austrian Society of thoracic Surgery; Vienna. 2019.

13.

Tsao M. EGFR testing. In: Mok TC, Hirsch FR, editors. IASLC atlas of EGFR testing in lung cancer. North Fort Myers: Editorial Rx Press; 2017. pp. 19–26.

14.

Yoshida A. ALK Testing with FISH. 2016. pp. 41–52.

15.

Lung Cancer, Nonsmall Cell Lung Cancer (NSCLC)/Bronchialkarzinom (OMIM #211980). In: Bundesministerium Arbeit S, Gesundheit und Konsumentenschutz, editor. Somatische Mutationen – Molekulare Hämatoonkologie, Molekularpathologie. Austria 2018.

16.

The Netherlands Cancer Institute. Lung Cancer Early Molecular Assessment Trial (LEMA). ClinicalTrialsgov Edited by National Library of Medicine. Bethesda, Maryland: National Institute of Health; 2017. ClinicalTrials.gov Identifier: NCT02894853

17.

Hochmair MF, Holzer S, Illini O, Setinek U, Krenbek D, Georg B, Draxler H, Weinlinger C, Watzka S, Müller MR, Huemer F, Dworan N, Burghuber OC, Valipour A. EGFR, EML4-ALK, ROS1 and BRAF testing in Austrian patients with NSCLC. In: Department of respiratory and critical care medicine KN-KF. Proceedings of the 43rd Annual Meeting of the Austrian Societies of Pneumology and Thoracic Surgery; Vienna. 2019.

18.

Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl 1):S24–S31. https://doi.org/10.1038/onc.2009.198.CrossRefPubMedPubMedCentral

19.

Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500. https://doi.org/10.1126/science.1099314.CrossRefPubMed

20.

Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23(4):857–65. https://doi.org/10.1200/JCO.2005.08.043.CrossRefPubMed

21.

Sequist LV, Joshi VA, Janne PA, Bell DW, Fidias P, Lindeman NI, et al. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res. 2006;12(14 Pt 2):4403s–8s. https://doi.org/10.1158/1078-0432.CCR-06-0099.CrossRefPubMed

22.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57. https://doi.org/10.1056/NEJMoa0810699.CrossRefPubMed

23.

Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010;5(10):1706–13. https://doi.org/10.1097/JTO.0b013e3181f1c8de.CrossRefPubMed

24.

Coupkova H, Vyzula R. Afatinib in the treatment of advanced non-small cell lung cancer with rare EGFR (in exon 18-T179X) mutation—a case report. Klin Onkol. 2018;31(5):380–3. https://doi.org/10.14735/amko2018380.CrossRefPubMed

25.

Castellano GM, Aisner J, Burley SK, Vallat B, Yu HA, Pine SR, et al. A novel acquired Exon 20 EGFR M766Q mutation in lung adenocarcinoma mediates osimertinib resistance but is sensitive to neratinib and poziotinib. J Thorac Oncol. 2019; https://doi.org/10.1016/j.jtho.2019.06.015.CrossRefPubMedPubMedCentral

26.

Popper HH, Gruber-Mösenbacher U, Müllauer L, Hutarew G, Vesely M, Pirker R, et al. Recommendations of the Austrian working group on lung pathology and oncology for predictive molecular and Immunohisochemical testing in non-small-cell lung cancer. memo. 2013;6:83–91. https://doi.org/10.1007/s12254-013-0087-7 CrossRef

27.

Aisner D. Reporting, interpretations, and quality assurence. In: Mok TC, Carbone DP, Hirsch FR, editors. IASLC Atlas of EGFR testing in lung cancer. North Fort Myers: Editorial Rx Press; 2017. pp. 53–8.

28.

Hochmair MJ, Buder A, Schwab S, Burghuber OC, Prosch H, Hilbe W, et al. Liquid-biopsy-based identification of EGFR T790M mutation-mediated resistance to afatinib treatment in patients with advanced EGFR mutation-positive NSCLC, and subsequent response to Osimertinib. Target Oncol. 2019;14(1):75–83. https://doi.org/10.1007/s11523-018-0612-z.CrossRefPubMed

29.

Santarpia M, Karachaliou N, Gonzalez-Cao M, Altavilla G, Giovannetti E, Rosell R. Feasibility of cell-free circulating tumor DNA testing for lung cancer. Biomark Med. 2016;10(4):417–30. https://doi.org/10.2217/bmm.16.6.CrossRefPubMed

30.

Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, et al. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget. 2016;7(6):6984–93. https://doi.org/10.18632/oncotarget.6874.CrossRefPubMedPubMedCentral

31.

Sueoka-Aragane N, Katakami N, Satouchi M, Yokota S, Aoe K, Iwanaga K, et al. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study. Cancer Sci. 2016;107(2):162–7. https://doi.org/10.1111/cas.12847.CrossRefPubMedPubMedCentral

32.

Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6:6377. https://doi.org/10.1038/ncomms7377.CrossRefPubMed

33.

Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165–e72. https://doi.org/10.1016/s1470-2045(14)71180-5.CrossRefPubMedPubMedCentral

34.

Suda K, Murakami I, Sakai K, Mizuuchi H, Shimizu S, Sato K, et al. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. Sci Rep. 2015;5:14447. https://doi.org/10.1038/srep14447.CrossRefPubMedPubMedCentral

35.

Yang J. EGFR gene mutations. In: Mok TC, Carbone DP, Hirsch FR, editors. IASLC atlas of EGFR testing in lung cancer. North Fort Myers: Editorial Rx Press; 2017. pp. 33–41.

36.

Buder A, Setinek U, Hochmair MJ, Schwab S, Kirchbacher K, Keck A, et al. EGFR mutations in cell-free plasma DNA from patients with advanced lung adenocarcinoma: improved detection by droplet digital PCR. Target Oncol. 2019;14(2):197–203. https://doi.org/10.1007/s11523-019-00623-x.CrossRefPubMedPubMedCentral

37.

Buder A, Hochmair MJ, Schwab S, Bundalo T, Schenk P, Errhalt P, et al. Cell-free plasma DNA-guided treatment with osimertinib in patients with advanced EGFR-mutated NSCLC. J Thorac Oncol. 2018;13(6):821–30. https://doi.org/10.1016/j.jtho.2018.02.014.CrossRefPubMed

38.

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–53. https://doi.org/10.1200/jco.2009.22.6993.CrossRefPubMedPubMedCentral

39.

Wong DW‑S, Leung EL‑H, So KK‑T, Tam IY‑S, Sihoe AD‑L, Cheng L‑C, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115(8):1723–33. https://doi.org/10.1002/cncr.24181.CrossRefPubMed

40.

Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3(1):13–7. https://doi.org/10.1097/JTO.0b013e31815e8b60.CrossRefPubMed

41.

Nicholson A. Sample acquisition, processing, and general diagnostic procedures. In: Tsao MH, Hirsch FR, Yatabe Y, editors. IASLC Atlas of ALK and ROS1 testing in lung cancer. 2nd ed. North Fort Myers: Editorila Rx PRess; 2016. pp. 19–23.

42.

Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011;6(3):466–72. https://doi.org/10.1097/JTO.0b013e31820b82e8.CrossRefPubMed

43.

Hutarew G, Hauser-Kronberger C, Strasser F, Llenos IC, Dietze O. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH. Histopathology. 2014;65(3):398–407. https://doi.org/10.1111/his.12399.CrossRefPubMed

44.

Lantuéjoul S. Comparison of different assa platforms for ALK testing. In: Tsao MH, Hirsch FR, Yatabe Y, editors. IASLC Atlas of ALK and ROS1 testing in lung cancer. North Fort Myers: Editorial Rx PRess; 2016. pp. 73–83.

45.

Yoshida T, Oya Y, Tanaka K, Shimizu J, Horio Y, Kuroda H, et al. Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2016;34(28):3383–9. https://doi.org/10.1200/JCO.2015.65.8732.CrossRefPubMed

46.

Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. Oncologist. 2016;21(6):762–70. https://doi.org/10.1634/theoncologist.2015-0497.CrossRefPubMedPubMedCentral

47.

Thunissen E. Reporting of ALK and ROS1 testing. In: Tsao MS, Hirsch FR, Yasushi Y, editors. IASLC Atlas of ALK and ROS1 testing in lung cancer. North Fort Myers: Editorial Rx Press; 2016. pp. 91–4.

48.

Steuer CE, Ramalingam SS. ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options. Cancer. 2014; https://doi.org/10.1002/cncr.28597.CrossRefPubMed

49.

Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6(10):1118–33. https://doi.org/10.1158/2159-8290.CD-16-0596.CrossRefPubMedPubMedCentral

50.

McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, et al. Resistance mechanisms to targeted therapies in ROS1(+) and ALK(+) non-small cell lung cancer. Clin Cancer Res. 2018;24(14):3334–47. https://doi.org/10.1158/1078-0432.CCR-17-2452.CrossRefPubMedPubMedCentral

51.

Wu W, Haderk F, Bivona TG. Non-canonical thinking for targeting ALK-fusion onco-proteins in lung cancer. Cancers. 2017; https://doi.org/10.3390/cancers9120164.CrossRefPubMedPubMedCentral

52.

Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, et al. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability. Oncotarget. 2015;6(12):10577–85. https://doi.org/10.18632/oncotarget.3387.CrossRefPubMedPubMedCentral

53.

Lee SE, Lee B, Hong M, Song JY, Jung K, Lira ME, et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Mod Pathol. 2015;28(4):468–79. https://doi.org/10.1038/modpathol.2014.107.CrossRefPubMed

54.

Hirsch FR, Tsao MS, et al. Candidates for ALK and ROS1 Testing. In: Tsao MS, Hirsch F, Yasushi Y, editors. IASLC Atlas of ALK and ROS1 Testing in Lung Cancer. Noth Fort Myers: Editorial Rx Press; 2016. pp. 15–8.

55.

Sholl LY, Nicholson AG, lantejoul S, Hirsch FR, et al. ROS1 Testind with IHC. In: Tsao MH, Hirsch FR, Yatabe Y, editors. IASLC Atlas of ALK and ROS1 testing in lung cancer. North Fort Myers: Editorial Rx PRess; 2016. pp. 35–40.

56.

Yoshida A, Tsuta K, Wakai S, Arai Y, Asamura H, Shibata T, et al. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol. 2014;27(5):711–20. https://doi.org/10.1038/modpathol.2013.192.CrossRefPubMed

57.

Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, et al. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study. J Thorac Oncol. 2019; https://doi.org/10.1016/j.jtho.2019.07.005.CrossRefPubMed

58.

Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18(16):4449–57. https://doi.org/10.1158/1078-0432.CCR-11-3351.CrossRefPubMed

59.

Mescam-Mancini L, Lantuejoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, et al. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer. 2014;83(2):168–73. https://doi.org/10.1016/j.lungcan.2013.11.019.CrossRefPubMed

60.

Varella-Garcia M. ROS1 testing with FISH. In: Tsao MS, Hirsch FR, Yatabe Y, editors. IASLC atlas of ALK and ROS1 testing in lung cancer. North Fort Myers: Editorial Rx Press; 2016. pp. 52–62.

61.

Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res. 2015;21(1):166–74. https://doi.org/10.1158/1078-0432.ccr-14-1385.CrossRefPubMed

62.

Guisier F, Piton N, Salaun M, Thiberville L. ROS1-rearranged NSCLC with secondary resistance mutation: case report and current perspectives. Clin Lung Cancer. 2019; https://doi.org/10.1016/j.cllc.2019.06.007.CrossRefPubMed

63.

Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G. KRAS-mutant non-small cell lung cancer: from biology to therapy. Lung Cancer. 2018;124:53–64. https://doi.org/10.1016/j.lungcan.2018.07.013.CrossRefPubMed

64.

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology. Arch Pathol Lab Med. 2018;142(3):321–46. https://doi.org/10.5858/arpa.2017-0388-CP.CrossRefPubMed

65.

Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019; https://doi.org/10.1038/s41586-019-1694-1.CrossRefPubMed

66.

Litvak AM, Paik PK, Woo KM, Sima CS, Hellmann MD, Arcila ME, et al. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. J Thorac Oncol. 2014;9(11):1669–74. https://doi.org/10.1097/JTO.0000000000000344.CrossRefPubMedPubMedCentral

67.

Penault-Llorca F, Rudzinski ER, Sepulveda AR. Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol. 2019;72(7):460–7. https://doi.org/10.1136/jclinpath-2018-205679.CrossRefPubMed

68.

Takeda M, Sakai K, Terashima M, Kaneda H, Hayashi H, Tanaka K, et al. Clinical application of amplicon-based next-generation sequencing to therapeutic decision-making in lung cancer. Ann Oncol. 2015; https://doi.org/10.1093/annonc/mdv475.CrossRefPubMed

69.

Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015;4(2):156–64. https://doi.org/10.3978/j.issn.2218-6751.2014.11.11.CrossRefPubMedPubMedCentral

70.

Hechtman JF, Benayed R, Hyman DM, Drilon A, Zehir A, Frosina D, et al. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41(11):1547–51. https://doi.org/10.1097/PAS.0000000000000911.CrossRefPubMedPubMedCentral

71.

Gatalica Z, Xiu J, Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019;32(1):147–53. https://doi.org/10.1038/s41379-018-0118-3.CrossRefPubMed

72.

Marchio C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30(9):1417–27. https://doi.org/10.1093/annonc/mdz204.CrossRefPubMed

73.

Kim EK, Kim KA, Lee CY, Shim HS. The frequency and clinical impact of HER2 alterations in lung adenocarcinoma. PLoS ONE. 2017;12(2):e171280. https://doi.org/10.1371/journal.pone.0171280.CrossRefPubMedPubMedCentral

74.

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, et al. Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-Overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers. Clin Cancer Res. 2019;25(1):64–72. https://doi.org/10.1158/1078-0432.CCR-18-1590.CrossRefPubMed

75.

Liu S, Li S, Hai J, Wang X, Chen T, Quinn MM, et al. Targeting HER2 aberrations in non-small cell lung cancer with osimertinib. Clin Cancer Res. 2018;24(11):2594–604. https://doi.org/10.1158/1078-0432.CCR-17-1875.CrossRefPubMedPubMedCentral

76.

Schildhaus HU, Schultheis AM, Ruschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, et al. MET amplification status in therapy-naive adeno- and squamous cell carcinomas of the lung. Clin Cancer Res. 2015;21(4):907–15. https://doi.org/10.1158/1078-0432.CCR-14-0450.CrossRefPubMed

77.

Kim JH, Kim HS, Kim BJ. MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review. Oncotarget. 2017;8(43):75500–8. https://doi.org/10.18632/oncotarget.20824.CrossRefPubMedPubMedCentral

78.

Mino-Kenudson M. Pulmonary pathology: SY22‑1 Immunohistochemistry for lung cancer predictive biomarkers. Pathology. 2014;46(Suppl 2):S39. https://doi.org/10.1097/01.PAT.0000454219.29630.ac.CrossRef

79.

Bronte GU, Verlicchi A, Cravero P, Delmonte A, Crino L. Targeting RET-rearranged non-small-cell lung cancer: future prospects. Lung Cancer. 2019;10:27–36.PubMedPubMedCentral

80.

Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R. Leenders F et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 2014;4(4):415–22. https://doi.org/10.1158/2159-8290.CD-13-0633.CrossRefPubMed

81.

Shin DH, Lee D, Hong DW, Hong SH, Hwang JA, Lee BI, et al. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. Oncotarget. 2016;7(43):69450–65. https://doi.org/10.18632/oncotarget.11913.CrossRefPubMedPubMedCentral

82.

Jones MR, Lim H, Shen Y, Pleasance E, Ch’ng C, Reisle C, et al. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Ann Oncol. 2017;28(12):3092–7. https://doi.org/10.1093/annonc/mdx523.CrossRefPubMed

83.

Gay ND, Wang Y, Beadling C, Warrick A, Neff T, Corless CL, et al. Durable response to afatinib in lung adenocarcinoma harboring NRG1 gene fusions. J Thorac Oncol. 2017;12(8):e107–e10. https://doi.org/10.1016/j.jtho.2017.04.025.CrossRefPubMed

84.

Kim HS, Han JY, Shin DH, Lim KY, Lee GK, Kim JY, et al. EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion. Lung Cancer. 2018;124:71–5. https://doi.org/10.1016/j.lungcan.2018.07.026.CrossRefPubMed

85.

Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, et al. Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers. Cancer Discov. 2018;8(6):686–95. https://doi.org/10.1158/2159-8290.CD-17-1004.CrossRefPubMedPubMedCentral

86.

Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5(8):860–77. https://doi.org/10.1158/2159-8290.cd-14-1236.CrossRefPubMedPubMedCentral

87.

Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer. 2019;106:144–59. https://doi.org/10.1016/j.ejca.2018.11.002.CrossRefPubMed

88.

Brcic L, Stanzer S, Krenbek D, Gruber-Moesenbacher U, Absenger G, Quehenberger F, et al. Immune cell landscape in therapy-naive squamous cell and adenocarcinomas of the lung. Virchows Arch. 2018;472(4):589–98. https://doi.org/10.1007/s00428-018-2326-0.CrossRefPubMedPubMedCentral

89.

Chatterjee S, Lesniak WG, Gabrielson M, Lisok A, Wharram B, Sysa-Shah P, et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget. 2016;7(9):10215–27. https://doi.org/10.18632/oncotarget.7143.CrossRefPubMedPubMedCentral

90.

Ilie M, Hofman V, Dietel M, Soria JC, Hofman P. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch. 2016;468(5):511–25. https://doi.org/10.1007/s00428-016-1910-4.CrossRefPubMed

91.

Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12(2):208–22. https://doi.org/10.1016/j.jtho.2016.11.2228.CrossRefPubMed

92.

Schildhaus HU. Predictive value of PD-L1 diagnostics. Pathologe. 2018;39(6):498–519. https://doi.org/10.1007/s00292-018-0507-x.CrossRefPubMed

93.

Vannitamby A, Hendry S, Irving L, Steinfort D, Bozinovski S. Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens. Lung Cancer. 2019;134:233–7. https://doi.org/10.1016/j.lungcan.2019.06.029.CrossRefPubMed

94.

Udall M, Rizzo M, Kenny J, Doherty J, Dahm S, Robbins P, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol. 2018;13(1):12. https://doi.org/10.1186/s13000-018-0689-9.CrossRefPubMedPubMedCentral

95.

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56. https://doi.org/10.1093/annonc/mdy495.CrossRefPubMed

96.

Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–104. https://doi.org/10.1056/NEJMoa1801946.CrossRefPubMedPubMedCentral

97.

Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD‑1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8. https://doi.org/10.1126/science.aaa1348.CrossRefPubMedPubMedCentral

98.

Skoulidis FA, Arbour KC, Hellmann MD, Patil PD, Elpi Marmarelis E, Awad ME, et al. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. J Clin Oncol. 2019; https://doi.org/10.1200/JCO.2019.37.15_suppl.102.CrossRefPubMedPubMedCentral

Titel: The 2020 update of the recommendations of the Austrian working group on lung pathology and oncology for the diagnostic workup of non-small cell lung cancer with focus on predictive biomarkers
verfasst von: Prof. Helmut H. Popper, M.D.
Ulrike Gruber-Mösenbacher
Georg Pall
Leonhard Müllauer
Maximilian Hochmair
Dagmar Krenbek
Luka Brcic
Katja Schmitz
Bernd Lamprecht
Josef Eckmayr
Wolfgang Hilbe
Georg Hutarew
Peter Errhalt
Rainer Kolb
Robert Pirker
Ulrike Setinek
Gerald Webersinke
Gudrun Absenger
Tamara Hernler
Markus Rauter
Richard Wasicky
Publikationsdatum: 24.01.2020
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-019-00565-0

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

CAR(-T)s are on the road

Evidence-based follow-up for breast cancer

CAR-T cells in multiple myeloma: current status

The golden anniversary of the Austrian Society of Hematology and Medical Oncology (OeGHO)

Evidence-based follow-up in renal cell carcinoma

CAR T-cell therapy in diffuse large B-cell lymphoma